Claims for Patent: 9,765,028

Summary for Patent: 9,765,028

Title:	Crystalline freebase forms of a biphenyl compound
Abstract:	The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Inventor(s):	Woollam; Grahame (Basel, CH)
Assignee:	Theravance Biopharma R&D IP, LLC (South San Francisco, CA)
Application Number:	15/206,877
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,765,028
Patent Claims:	1. Crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}-ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta. values of 6.6.+-.0.1, 13.1.+-.0.1, 18.6.+-.0.1, 19.7.+-.0.1, and 20.2.+-.0.1; and further characterized by having five or more additional diffraction peaks at 2.theta. values selected from 8.8.+-.0.1, 10.1.+-.0.1, 11.4.+-.0.1, 11.6.+-.0.1, 14.8.+-.0.1, 15.2.+-.0.1, 16.1.+-.0.1, 16.4.+-.0.1, 16.9.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 19.3.+-.0.1, 19.9.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 2. Crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}-ethyl)piper- idin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta.values selected from 6.6.+-.0.1, 11.4.+-.0.1, 13.1.+-.0.1, 16.1.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 18.6.+-.0.1, 19.3.+-.0.1, 19.7.+-.0.1, 19.9.+-.0.1, 20.2.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 3. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta. values of 6.6.+-.0.1, 13.1.+-.0.1, 18.6.+-.0.1, 19.7.+-.0.1, and 20.2.+-.0.1; and further characterized by having five or more additional diffraction peaks at 2.theta. values selected from 8.8.+-.0.1, 10.1.+-.0.1, 11.4.+-.0.1, 11.6.+-.0.1, 14.8.+-.0.1, 15.2.+-.0.1, 16.1.+-.0.1, 16.4.+-.0.1, 16.9.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 19.3.+-.0.1, 19.9.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 4. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2.theta. values selected from 6.6.+-.0.1, 11.4.+-.0.1, 13.1.+-.0.1, 16.1.+-.0.1, 17.5.+-.0.1, 18.2.+-.0.1, 18.6.+-.0.1, 19.3.+-.0.1, 19.7.+-.0.1, 19.9.+-.0.1, 20.2.+-.0.1, 20.8.+-.0.1, 21.1.+-.0.1, 21.7.+-.0.1, and 22.3.+-.0.1. 5. Crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester characterized by a powder x-ray diffraction pattern having peak positions in accordance with the peak positions shown in FIG. 1. 6. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier; and (b) crystalline freebase Form III of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyfl]methylamino}ethyl)pipe- ridin-4-yl ester characterized by a powder x-ray diffraction pattern having peak positions in accordance with the peak positions shown in FIG. 1.